182 related articles for article (PubMed ID: 36860188)
1. Development and Delivery of a Hands-On Short Course in Adeno-Associated Virus Manufacturing to Support Growing Workforce Needs in Gene Therapy.
Overton L; Boi C; Shastry S; Smith-Moore C; Balchunas J; Sambandan D; Gilleskie G
Hum Gene Ther; 2023 Apr; 34(7-8):259-272. PubMed ID: 36860188
[TBL] [Abstract][Full Text] [Related]
2. Challenges in scaling up AAV-based gene therapy manufacturing.
Jiang Z; Dalby PA
Trends Biotechnol; 2023 Oct; 41(10):1268-1281. PubMed ID: 37127491
[TBL] [Abstract][Full Text] [Related]
3. Synthetic Biology Design as a Paradigm Shift toward Manufacturing Affordable Adeno-Associated Virus Gene Therapies.
Collins LT; Ponnazhagan S; Curiel DT
ACS Synth Biol; 2023 Jan; 12(1):17-26. PubMed ID: 36627108
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive hands-on training for influenza vaccine manufacturing: a WHO-BARDA-BTEC partnership for global workforce development.
Ruiz J; Gilleskie GL; Brown P; Burnett B; Carbonell RG
Biochem Mol Biol Educ; 2014; 42(5):414-9. PubMed ID: 25132407
[TBL] [Abstract][Full Text] [Related]
5. Treatment to cure: Advancing AAV gene therapy manufacture.
Young P
Drug Discov Today; 2023 Jul; 28(7):103610. PubMed ID: 37169134
[TBL] [Abstract][Full Text] [Related]
6. Manufacturing and characterizing AAV-based vectors for use in clinical studies.
Wright JF
Gene Ther; 2008 Jun; 15(11):840-8. PubMed ID: 18418418
[TBL] [Abstract][Full Text] [Related]
7. Cellular pathways of recombinant adeno-associated virus production for gene therapy.
Sha S; Maloney AJ; Katsikis G; Nguyen TNT; Neufeld C; Wolfrum J; Barone PW; Springs SL; Manalis SR; Sinskey AJ; Braatz RD
Biotechnol Adv; 2021; 49():107764. PubMed ID: 33957276
[TBL] [Abstract][Full Text] [Related]
8. Manufacturing Challenges and Rational Formulation Development for AAV Viral Vectors.
Srivastava A; Mallela KMG; Deorkar N; Brophy G
J Pharm Sci; 2021 Jul; 110(7):2609-2624. PubMed ID: 33812887
[TBL] [Abstract][Full Text] [Related]
9. Quality Control Testing, Characterization and Critical Quality Attributes of Adeno-Associated Virus Vectors Used for Human Gene Therapy.
Wright JF
Biotechnol J; 2021 Jan; 16(1):e2000022. PubMed ID: 33146911
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in the Analysis Full/Empty Capsid Ratio and Genome Integrity of Adeno-associated Virus (AAV) Gene Delivery Vectors.
Hajba L; Guttman A
Curr Mol Med; 2020; 20(10):806-813. PubMed ID: 32748744
[TBL] [Abstract][Full Text] [Related]
11. Recombinant Adeno-Associated Virus Quality Control for Non-Clinical and Clinical Vectors: How an Unregulated Commercial Sector Can Compromise Development of New Gene Therapies.
Kotin RM; Wright JF
Hum Gene Ther; 2019 Dec; 30(12):1447-1448. PubMed ID: 31860397
[No Abstract] [Full Text] [Related]
12. The gap between development and manufacturing in gene therapy: Strategic options for overcoming traps.
Nishida Y; Kodama K; Sengoku S
Drug Discov Today; 2023 Feb; 28(2):103429. PubMed ID: 36334648
[TBL] [Abstract][Full Text] [Related]
13. Moving from the bench towards a large scale, industrial platform process for adeno-associated viral vector purification.
Adams B; Bak H; Tustian AD
Biotechnol Bioeng; 2020 Oct; 117(10):3199-3211. PubMed ID: 32573761
[TBL] [Abstract][Full Text] [Related]
14. scAAVengr, a transcriptome-based pipeline for quantitative ranking of engineered AAVs with single-cell resolution.
Öztürk BE; Johnson ME; Kleyman M; Turunç S; He J; Jabalameli S; Xi Z; Visel M; Dufour VL; Iwabe S; Pompeo Marinho LFL; Aguirre GD; Sahel JA; Schaffer DV; Pfenning AR; Flannery JG; Beltran WA; Stauffer WR; Byrne LC
Elife; 2021 Oct; 10():. PubMed ID: 34664552
[TBL] [Abstract][Full Text] [Related]
15. High-Throughput
Westhaus A; Cabanes-Creus M; Rybicki A; Baltazar G; Navarro RG; Zhu E; Drouyer M; Knight M; Albu RF; Ng BH; Kalajdzic P; Kwiatek M; Hsu K; Santilli G; Gold W; Kramer B; Gonzalez-Cordero A; Thrasher AJ; Alexander IE; Lisowski L
Hum Gene Ther; 2020 May; 31(9-10):575-589. PubMed ID: 32000541
[TBL] [Abstract][Full Text] [Related]
16. Adeno-associated virus vectors for gene therapy: more pros than cons?
Monahan PE; Samulski RJ
Mol Med Today; 2000 Nov; 6(11):433-40. PubMed ID: 11074369
[TBL] [Abstract][Full Text] [Related]
17. Assessment of quality attributes for adeno-associated viral vectors.
Tustian AD; Bak H
Biotechnol Bioeng; 2021 Nov; 118(11):4186-4203. PubMed ID: 34309017
[TBL] [Abstract][Full Text] [Related]
18. Optimization of the quality by design approach for gene therapy products: A case study for adeno-associated viral vectors.
Tanaka T; Hanaoka H; Sakurai S
Eur J Pharm Biopharm; 2020 Oct; 155():88-102. PubMed ID: 32784043
[TBL] [Abstract][Full Text] [Related]
19. Adeno-associated virus vectors: potential applications for cancer gene therapy.
Li C; Bowles DE; van Dyke T; Samulski RJ
Cancer Gene Ther; 2005 Dec; 12(12):913-25. PubMed ID: 15962012
[TBL] [Abstract][Full Text] [Related]
20. Adeno-associated viral vectors for gene therapy of inherited retinal degenerations.
Flannery JG; Visel M
Methods Mol Biol; 2013; 935():351-69. PubMed ID: 23150381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
